• Recruiting

NCT03091257: Phase 1 - Dabrafenib and/or Trametinib in Patients With Relapsed Refractory Myeloma

Updated: Jun 15

Multiple Myeloma Research Consortium

NCT03091257: Phase 1 - Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

dabrafenib myeloma

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma


This research study is studying a targeted therapy as a possible treatment for multiple myeloma.

The names of the study drugs involved in this study are:

Trametinib

Dabrafenib


Sponsor

Massachusetts General Hospital


Collaborators

Novartis

Multiple Myeloma Research Consortium

Barbara Ann Karmanos Cancer Institute

 

ClinicalTrials.gov Identifier: NCT03091257

Official Title: An Open-label, Pilot Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

First Posted : March 27, 2017


Click here for ClinicalTrials.gov

 

Dabrafenib: National Cancer Institute

Dabrafenib: MedlinePlus Drug Information


Trametinib: National Cancer Institute

Trametinib: MedlinePlus Drug Information

 

Drug: Dabrafenib

Drug: Trametinib

 

Locations

United States, Massachusetts

United States, Michigan









Posts Archive